spacer
home > ebr > winter 2018 > fight against resistance
PUBLICATIONS
European Biopharmaceutical Review

Fight Against Resistance

Microbial resistance to antibiotics is rising. Keiji Fukuda at the WHO has described antimicrobial resistance (AMR) as a major threat to global public health, stating “Without urgent, coordinated action by many stakeholders, the world is headed for a post-antibiotic era, in which common infections and minor injuries which have been treatable for decades can once again kill” (1). AMR is a natural and inevitable phenomenon, an outcome of natural selection; bacteria always have evolved to resist threats to their survival and will continue to do so. AMR cannot be completely prevented, but urgent action must be taken to curtail it and minimise its impact on global health.

Excessive and inappropriate use of antibiotics and antimicrobials more widely – combined with inadequate infection control and poor hygiene – are the main factors contributing to the spread of resistance, according to the European Commission’s statement on AMR (2). Decades of over-prescription and off-prescription use, in both humans and animals, have exacerbated the problem, and development of new antibiotics has all but stalled, with far fewer new drugs being licensed in the last couple of decades than in the early and mid-20th century.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Michele Barbour is Chief Executive Officer of Pertinax Pharma. Pertinax technology was developed by her research group at the University of Bristol, UK, where she is Reader in biomaterials and Deputy Head of Bristol Dental School, UK. Michele is the author of over 50 peer-reviewed publications and a leading textbook. She founded Pertinax Pharma in 2015 to commercialise the technology that allows the controlled and sustained release of the antiseptic chlorhexidine.
spacer
Dr Michele Barbour
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Novo Nordisk Pharmatech A/S signs distribution agreement with DKSH for twelve countries in Asia Pacific

Novo Nordisk Pharmatech A/S and DKSH, have partnered to provide high-quality cGMP quaternary ammonium compounds in twelve countries across Asia Pacific
More info >>

White Papers

pAVEway™ expression system for the efficient expression of therapeutic proteins

Fujifilm Diosynth Biotechnologies

One of the major bottlenecks in the production of biopharmaceuticals is the efficient expression of therapeutic proteins in microbial or mammalian cells. The Escherichia coli pAVEway™ expression system described here has been developed to ensure high product titres and efficient scale up to GMP manufacture, whilst minimising many common issues seen in other expression systems, such as ‘leaky’ expression (expression of recombinant protein in the absence of inducer).
More info >>

 
Industry Events

Drug Delivery Partnerships 2019

28-30 January 2019, PGA National Resort & Spa in Palm Beach Gardens, FL

For 23 years, DDP has been the world’s largest drug delivery meeting place to accelerate drugs to market and lengthen lifecycles for long term profitability by finding new partners, new drug delivery technologies, and new formulation development strategies. Year after year this event brings together top scientists and business development leaders from Biotech, Pharma, Generics, Specialty Pharma and Drug Delivery companies to share, discuss, and collaborate. If you work in drug delivery, commercialization/licensing, med device, formulation, biologics, biosimilars, and similar areas, you can’t miss this event!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement